Please login to the form below

Not currently logged in
Email:
Password:

Parsabiv

This page shows the latest Parsabiv news and features for those working in and with pharma, biotech and healthcare.

Amgen’s R&D chief Sean Harper retires to seek biotech post

Amgen’s R&D chief Sean Harper retires to seek biotech post

Bradway said two new products – Aimovig (erenumab) for migraine and Sensipar follow-up Parsabiv (etelcalcetide) for chronic kidney disease – had started well, and the quarter was also marked by the launch ... Parsabiv meanwhile made $73m after making

Latest news

  • NICE set to back Parsabiv for kidney disease complication NICE set to back Parsabiv for kidney disease complication

    In draft guidance, the cost-effectiveness agency is backing use of Amgen's Parsabiv (etelcalcetide) for secondary hyperparathyroidism caused by CKD in patients on haemodialysis, but only for patients who cannot ... Parsabiv was approved by the EMA last

  • Amgen's chronic kidney disease drug Parsabiv cleared in US Amgen's chronic kidney disease drug Parsabiv cleared in US

    Amgen has finally been granted FDA approval for its Parsabiv therapy for a complication of chronic kidney disease (CKD), after being turned down by the US regulator last summer. ... to be used in clinical practice, the monthly costs of Parsabiv and

  • Amgen wins European approval for Parsabiv Amgen wins European approval for Parsabiv

    European regulators have approved Amgen's Parsabiv (etelcalcetide), licensing it for secondary hyperparathyroidism (sHPT) in adult patients with chronic kidney disease (CKD) on hemodialysis. ... In contrast, Parsabiv is administered as an infusion during

  • FDA knocks back Amgen's chronic kidney disease treatment FDA knocks back Amgen's chronic kidney disease treatment

    Parsabiv was hoped to equal or exceed solid earner Sensipar.  . Amgen has been dealt a blow to its late-stage pipeline by the FDA, which has declined to approve a ... In contrast, Parsabiv is administered as an infusion during dialysis, side-stepping

More from news
Approximately 4 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

Switzerland
Switzerland: a life sciences hub
Switzerland has a rich diversity of pharma and biotech companies that sustain activity and help maintain its reputation as a highly innovative country...
Responding to dynamic shifts in value communications
OPEN Health’s Beth Lesher and Annemarie Clegg examine what the convergence of medical communications and market access means for pharmaceutical companies....
Doing what we can and having fun doing it: our fundraising month
Charities are facing a number of challenges just to stay afloat amidst the current COVID-19 pandemic. Fundraisers are being cancelled and public donations are not as abundant as they have...

Infographics